Norman Broadbent PLC

United Kingdom-based human capital consulting company, Norman Broadbent plc (NBB) is a provider of people solutions such as board and executive search, senior mid-level management, leadership and successor consulting, and mezzanine level search, social media consulting and research. These solutions are for diverse sectors such as energy, natural resources, financial services, travel & leisure, healthcare & life sciences, private equity, professional services and retail. In addition, the company also provides coaching to the Board and Leadership.

NBB-Financial highlights for H1 FY19

On 26th September 2019, the company announced its interim results for the period ended 30th June 2019. The company’s revenue surged by 13 per cent to £5,260 thousand in H1 FY19 as against £4,667 thousand in H1 FY18. The company’s gross profit stood at £3,522 thousand in H1 FY19 as against £3,290 thousand in H1 FY18. The company’s operating profit stood at £55 thousand in H1 FY19 as against operating loss of £234 thousand in H1 FY18. The company achieved a major landmark in posting a profit before taxation of £16 thousand in H1 FY19 against a loss of £265 thousand in H1 FY18. The company had cash balances of £258 thousand as at 30th June 2019 as against £260 thousand at 30th June 2018. The company’s equity shareholder’s funds stood at £1,294 thousand as at 30th June 2019 as against £1,268 thousand at 31st December 2018. The company’s net outflow of cash from operations stood at £529 thousand in H1 FY19. The company’s net inflow of cash from financing activities stood at £160 thousand in H1 FY19.

Â

NBB-Share price performance

Daily Chart as on 26-September-19, before the market close (Source: Thomson Reuters)

On 26th September 2019, while writing at 01:08 PM GMT, Norman Broadbent plc shares were clocking a current market price of GBX 8 per share; which was less by 3.03 per cent in comparison to the last traded price of the previous day. The company’s market capitalisation was at £4.50 million at the time of writing. On 13th February 2019, the shares of NBB have touched a new peak of GBX 12.90 and reached the lowest price level of GBX 3.00 on 23rd August 2019 in the last 52 weeks.

The stock’s traded volume was hovering around 20,000 at the time of writing before the market close. The company’s 5-day stock's average traded volume was 23,936.00; 30 days average traded volume- 254,371.40 and 90 days average traded volume – 89,745.09. The volatility of the company’s stock was 48 per cent lower as compared with the index taken as the benchmark, as the beta of the company’s stock was recorded at 0.52.

The shares of the company have delivered a negative return of 13.16 per cent in the last quarter. The company’s stock plunged by 31.25 per cent from the start of the year to till date. The company’s stock has given investors 19.51 per cent of a negative return in the last year.Â

Netcall PLC

Netcall PLC (NET) is engaged into communications, business processes services and workforce management related software and services for the healthcare, public and private sectors. The company not only designs and develops but also markets these products & services. The company has broadly three operating segments: corporate solutions, health solutions and public solutions. Case, record, document management and customer service forms part of the public solutions.

NET- Financial highlights for FY19

The company’s revenue surged by 5 per cent to £22.9 million in FY19 as against £21.9 million in FY18. The company’s cloud and product bookings surged by 62 per cent to £10.5 million (YoY basis) in FY19 as against £6.5 million in FY18. The company’s annual contract value was up by 10 per cent to £15.7 million (YoY basis) by the end of FY19 as against £14.2 million at 30th June 2018. The company’s adjusted EBITDA stood at £3.41 million in FY19 after increased investment, as against £5.42 million in FY18. The company’s profit before taxation surged to £0.75 million in FY19 as against £0.05 million in FY18. The company’s cash from operations stood at £6.84 million in FY19 as against £2.66 million in FY18. In addition, the company intends to recommend a final dividend of 0.20 pence per share in FY19. The company’s net cash stood at £1.14 million at 30th June 2019. The company’s capital expenditure this year was a tad more than the previous year. The company’s diluted earnings per share surged by 355 per cent to 0.41 pence in FY19 as against 0.09 pence in FY18.

NET-Share price performance

Daily Chart as on 26-September-19, before the market closed (Source: Thomson Reuters)

On 26th September 2019, while writing at 01:14 PM GMT, Netcall PLC shares were clocking a current market price of GBX 24.3 per share. The company’s market capitalisation was at £36.95 million at the time of writing.

On 27th September 2018, the shares of NET have touched a new peak of GBX 65.35 and reached the lowest price level of GBX 22.85 on 26th September 2019 in the last 52 weeks.

The stock’s traded volume was hovering around 165,315 at the time of writing before the market close. The company’s 5-day stock's average traded volume was 2,073,500.40; 30 days average traded volume- 433,395.37 and 90 days average traded volume – 214,885.82. The volatility of the company’s stock was 25 per cent lower as compared with the index taken as the benchmark, as the beta of the company’s stock was recorded at 0.75 with a dividend yield of 2.86 per cent.

The shares of the company have delivered a negative return of 33.77 per cent in the last quarter. The company’s stock plunged by 15.56 per cent from the start of the year to till date. The company’s stock has given investors 60.77 per cent of a negative return in the last year.Â

Â

Yourgene Health PLC

Yourgene Health PLC (YGEN) is into the business of gene analysis for pre-natal screenings for timely detection, monitoring and treatment of diseases along with foetal sex determination. The company has developed in house test called the IONA test, which is non-invasive and is capable of investigating the risk of Down's syndrome or other serious genetic diseases in foetus. Maternal blood sample is taken as an input to perform the test on DNA (deoxyribonucleic acid). The company was formerly known as Premaitha Health PLC.

YGEN-Financial highlights for FY19 period ended 31st March 2019

The company’s revenue surged by 45 per cent to £8.9 million in FY19 as against £6.1 million in FY18. The company’s gross profit also surged by 45 per cent to £4.6 million in FY19 as against £3.2 million in FY18. The company’s adjusted EBITDA loss was reduced by 29 per cent to £3.1 million in FY19 as against £4.4 million in FY18. The company’s operating loss reduced by 44 per cent to £4.8 million in FY19 as against £8.6 million in FY18. The company’s net cash stood at £1.0 million at year-end.

Â

YGEN-Share price performance

Daily Chart as on 26-September-19, before the market closed (Source: Thomson Reuters)

On 26th September 2019, while writing at 01:18 PM GMT, Yourgene Health PLC shares were clocking a current market price of GBX 12.25 per share; which was less by 1.05 per cent in comparison to the last traded price of the previous day. The company’s market capitalisation was at £74.96 million at the time of writing. On 18th February 2019, the shares of YGEN have touched a new peak of GBX 14.45 and reached the lowest price level of GBX 6.42 on 18th December 2018 in the last 52 weeks.

The stock’s traded volume was hovering around 478,664 at the time of writing before the market close. The company’s 5-day stock's average traded volume was 674,045.60; 30 days average traded volume- 551,168.73 and 90 days average traded volume – 1,015,293.78. The volatility of the company’s stock has very high as compared with the index taken as the benchmark, as the beta of the company’s stock was recorded at 2.89.

The shares of the company have delivered a negative return of 5.71 per cent in the last quarter. The company’s stock surged by 41.43 per cent from the start of the year to till date. The company’s stock has given investors 4.81 per cent of a negative return in the last year.Â

 

   
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK